William Blair Investment Management LLC raised its position in West Pharmaceutical Services Inc. (NYSE:WST) by 43.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,272,407 shares of the medical instruments supplier’s stock after purchasing an additional 383,646 shares during the period. William Blair Investment Management LLC owned about 1.71% of West Pharmaceutical Services worth $125,548,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in WST. Captrust Financial Advisors purchased a new position in West Pharmaceutical Services in the 4th quarter valued at about $125,000. Private Advisor Group LLC purchased a new position in West Pharmaceutical Services in the 3rd quarter valued at about $202,000. Alps Advisors Inc. purchased a new position in West Pharmaceutical Services in the 4th quarter valued at about $206,000. Tiedemann Wealth Management LLC purchased a new position in West Pharmaceutical Services in the 3rd quarter valued at about $207,000. Finally, Stephens Inc. AR purchased a new position in West Pharmaceutical Services in the 3rd quarter valued at about $210,000. Institutional investors own 94.37% of the company’s stock.
West Pharmaceutical Services stock opened at $90.00 on Thursday. West Pharmaceutical Services Inc. has a one year low of $77.97 and a one year high of $103.36. The company has a current ratio of 2.66, a quick ratio of 1.89 and a debt-to-equity ratio of 0.15. The company has a market cap of $6,726.11, a PE ratio of 45.23, a PEG ratio of 2.32 and a beta of 1.15.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, February 15th. The medical instruments supplier reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. West Pharmaceutical Services had a net margin of 9.42% and a return on equity of 14.68%. The company had revenue of $415.60 million during the quarter, compared to the consensus estimate of $416.90 million. During the same quarter in the prior year, the company posted $0.54 EPS. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. sell-side analysts forecast that West Pharmaceutical Services Inc. will post 2.85 earnings per share for the current year.
West Pharmaceutical Services declared that its board has approved a share buyback plan on Thursday, February 15th that authorizes the company to buyback 800,000 shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 2nd. Stockholders of record on Wednesday, April 18th will be paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date is Tuesday, April 17th. West Pharmaceutical Services’s dividend payout ratio is currently 28.14%.
A number of research analysts have issued reports on WST shares. Zacks Investment Research lowered shares of West Pharmaceutical Services from a “hold” rating to a “sell” rating in a report on Saturday, January 6th. Goldman Sachs started coverage on shares of West Pharmaceutical Services in a report on Wednesday, January 24th. They issued a “neutral” rating and a $110.00 target price on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. West Pharmaceutical Services currently has an average rating of “Hold” and an average price target of $108.17.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/03/22/william-blair-investment-management-llc-acquires-383646-shares-of-west-pharmaceutical-services-inc-wst.html.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.